Open AccessMiRNA‐145‐5p expression and prospective molecular mechanisms in the metastasis of prostate cancer
Author(s) -
Huang ZhiGuang,
Sun Yu,
Chen Gang,
Dang YiWu,
Lu HuiPing,
He Juan,
Cheng JiWen,
He MaoLin,
Li ShengHua
Publication year - 2021
Publication title -
iet systems biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.367
H-Index - 50
eISSN - 1751-8857
pISSN - 1751-8849
DOI - 10.1049/syb2.12011
Subject(s) - microrna , prostate cancer , metastasis , biomarker , cancer research , oncology , gene expression , cancer , gene , medicine , biology , computational biology , genetics
The clinicopathological implication and prospective molecular mechanisms of miRNA‐145‐5p in the metastasis of prostate cancer (PCa) stand unclear. Herein, it is found that miRNA‐145‐5p expression was remarkably reduced in 131 cases of metastatic PCa than 1371 cases of localised ones, as the standardised mean differences (SMD) was −1.26 and the area under the curve (AUC) was 0.86, based on miRNA‐chip and miRNA‐sequencing datasets. The potential targets of miRNA‐145‐5p in metastatic PCa ( n = 414) was achieved from the intersection of miRNA‐145‐5p transfected metastatic PCa cell line data, differential expression of metastatic PCa upregulated genes and online prediction databases. TOP2A was screened as one of the target hub genes by PPI network analysis, which was adversely related to miRNA‐145‐5p expression in both metastatic PCa ( r = −0.504) and primary PCa ( r = −0.281). Gene‐chip and RNA‐sequencing datasets, as well as IHC performed on clinical PCa samples, showed consistent upregulated expression of TOP2A mRNA and protein in PCa compared with non‐PCa. The expression of TOP2A mRNA was also significantly higher in metastatic than localised PCa with the SMD being 1.72 and the AUC of sROC being 0.91. In summary, miRNA‐145‐5p may participate in PCa metastasis by binding TOP2A and be useful as a biomarker for the detection of metastatic PCa.